Optimal management with class I and class III antiarrhythmic drugs should be done in the outpatient setting: Protagonist

Journal of Cardiovascular Electrophysiology

Volumn 10, Issue 3, 1999, Pages 472-481

  Thibault, Bernard ^b   Nattel, Stanley ^a  

^a MONTREAL HEART INSTITUTE   (Canada)

^b NONE

Author keywords

Antiarrhythmic drugs; Cost effectiveness; Health economics; Heart disease therapy; Long QT syndrome; Torsades de pointes

Indexed keywords

AMIODARONE; FLECAINIDE; PROPAFENONE; QUINIDINE; SOTALOL;

ANAMNESIS; ANTIARRHYTHMIC ACTIVITY; ARRHYTHMOGENESIS; BRADYCARDIA; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG INDUCED DISEASE; FEMALE; HEART ARRHYTHMIA; HOSPITAL COST; HOSPITALIZATION; HUMAN; LIVER TOXICITY; LONG QT SYNDROME; MALE; META ANALYSIS; MORTALITY; OUTPATIENT DEPARTMENT; POPULATION RISK; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SYNCOPE; TORSADE DES POINTES; TREATMENT CONTRAINDICATION; TREATMENT INDICATION;

EID: 0033033653     PISSN: 10453873     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1540-8167.1999.tb00701.x     Document Type: Conference Paper

References (89)

1. Hohnloser SH, Li YG: Drug treatment of atrial fibrillation: What have we learned? Curr Opin Cardiol 1997; 12:24-32.
2. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators: Preliminary report: Effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989:3321:406-412.
3. The Cardiac Arrhythmia Suppression Trial (CAST) II Investigators: Effects of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med 1992;327:227-233.
4. Coplen SE, Antman EM, Berlin JA, et al: Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion: A meta-analysis of randomized control trials. Circulation 1990;82:1106-1116.
5. Flaker GC, Blackshear JL, Mcbride R, et al: Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. J Am Coll Cardiol 1992;20:527-532.
6. Waldo AL, Camm AJ, deRuyter H, et al: Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. Lancet 1996;348:7-12.
7. Nattel S: Newer developments in the management of atrial fibrillation. Am Heart J 1995;130:1094-1106.
8. Wolf PA, Mitchell JB, Baker CS, et al: Mortality and hospital costs associated with atrial fibrillation. Circulation 1995;92:1-140.
9. Waktare JEP, Camm AJ: Acute treatment of atrial fibrillation: Why and when to maintain sinus rhythm. Am J Cardiol 1998;81:3C-15C.
10. Waldo AL, Prystowsky EN: Drug treatment of atrial fibrillation in the managed care era. Am J Cardiol 1998;81:23C-29C.
11. Dries DL, Exner DV, Gersh BJ, et al: Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: A retrospective analysis of the SOLVD trials. J Am Coll Cardiol 1998;32:695-703.
12. Benjamin EJ, Wolf PA, D'Agostino RB, et al: Impact of atrial fibrillation on the risk of death. The Framingham Heart Study. Circulation 1998;98:946-952.
13. Nattel S: Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 1998;37:567-577.
14. Ranger S, Nattel S: Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 1995;92:1300-1311.
15. Restivo M, Yin H, Caref EB, et al: Reentrant arrhythmias in the subacute infarction period: The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Circulation 1995;91:1236-1246.
16. Coromilas J, Saltman AE, Waldecker B, et al: Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 1995;91:2245-2263.
17. Morganroth J, Horowitz LN: Flecainide: Its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 1984;53:89B-94B.
18. Nattel S, Pederson DH, Zipes DP: Alterations in regional myocardial distribution and arrhythmogenic effects of aprindine produced by coronary artery occlusion in the dog. Cardiovasc Res 1981;15:80-85.
19. Carson DL, Cardinal R, Savard P, et al: Relationship between an arrhythmogenic action of lidocaine and its effects on excitation patterns in acutely ischemic porcine myocardium. J Cardiovasc Pharmacol 1986;8:126-136.
20. Lederman SN, Wenger TL, Bolster DE, et al: Effects of flecainide on occlusion and reperfusion arrhythmias in dogs. J Cardiovasc Pharmacol 1989;13:.541-546.
21. Greenberg HM, Dwyer EM Jr, Hochman JS, et al: Interaction of ischaemia and encainide/flecainide treatment: A proposed mechanism for the increased mortality in CAST I. Br Heart J 1995;74:631-635.
22. Dangman KH, Hoffman BF: In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide. J Pharmacol Exp Ther 1981;217:851-862.
23. Roden DM, Hoffman BF: Action potential prolongation and induction of abnormal automaticity by low quinidine concentrations in canine Purkinje fibers: Relationship to potassium and cycle length. Circ Res 1985;56: 857-867.
24. Nattel S, Quantz MA: Pharmacological response of quinidine induced early after depolarisations in canine cardiac Purkinje fibres: Insights into underlying ionic mechanisms. Cardiovasc Res 1988;22:808-817.
25. Volders PGA, Sipido KR, Vos MA, et al: Cellular basis of biventricular hypertrophy and arrhythmogenesis in dogs with chronic complete atrioventricular block and acquired torsade de pointes. Circulation 1998;98:1136-1147.
26. Halmos P: Direct current conversion of atrial fibrillation. Br Heart J 1966;28:302-308.
27. Byrne-Quinn E, Wing A: Maintenance of sinus rhythm after DC reversion of atrial fibrillation: A double-blind controlled trial of long-acting quinidine bisulphate. Br Heart J 1970;32:370-376.
28. Radford M, Evans D: Long-term results of DC reversion of atrial fibrillation. Br Heart J 1968;30:91-96.
29. Sodermark T, Edhag O, Sjogren A, et al: Effect of quinidine on maintaining sinus rhythm after cardioversion of atrial fibrillation or flutter: A multicentre study from Stockholm. Br Heart J 1975;37:486-492.
30. Hartel G, Louhija A, Konttinen A, et al: Value of quinidine in maintenance of sinus rhythm after electric conversion of atrial fibrillation. Br Heart J 1970;32:57-60.
31. Hillestad L, Bjerkelund C, Dale J, et al: Quinidine in maintenance of sinus rhythm after electroconversion of chronic atrial fibrillation: A controlled clinical study. Br Heart J 1971;33:518-521.
32. Boissel J, Wolf E, Gillet J, et al: Controlled trial of a long-acting quinidine for maintenance of sinus rhythm after conversion of sustained atrial fibrillation. Eur Heart J 1981;2:49-55.
33. Grande P, Sonne B, Pedersen A: A controlled study of digoxin and quinidine in patients DC reverted from atrial fibrillation to sinus rhythm. (Abstract) Circulation 1986;74:II-101.
34. Lloyd E, Gersh B, Forman R: The efficacy of quinidine and disopyramide in the maintenance of sinus rhythm after electroconversion from atrial fibrillation. S Afr Med J 1984;65:367-369.
35. Hohnloser S, van de Loo A, Baedeker F: Efficacy and proarrhythmic hazards of pharmacologic cardioversion of atrial fibrillation: Prospective comparison of sotalol versus quinidine. J Am Coll Cardiol 1995;26:852-858.
36. Crijns H, van Gelder I, van Gilst W, et al: Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation of atrial flutter. Am J Cardiol 1991;68:335-341.
37. Zehender M, Hohnloser S, Muller B, et al: Effects of amiodarone versus quinidine and verapamil in patients with chronic atrial fibrillation: Results of a comparative study and a 2-year follow-up. J Am Coll Cardiol 1992; 19:1054-1059.
38. Vitolo E, Tronci M, Larovere M, et al: Amiodarone versus quinidine in the prophylaxis of atrial fibrillation. Acta Cardiol 1981;6:431-444.
39. Juul-Moller S, Edvardsson N, Rehnqvist-Ahlberg N: Sotalol versus quinidine for the maintenance of sinus rhythm after direct current conversion of atrial fibrillation. Circulation 1990;82:1932-1939.
40. Coelho E, Pinto L, Luiz A, et al: Long-term results of conversion of atrial fibrillation by direct current counttershock. Cardiologia 1967;50:147-155.
41. Leendert M, van Wijk M, Den Heijer P, et al: Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 1989;13:32-36.
42. Naccarelli G, Dorian P, Hohnloser S: Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. Am J Cardiol 1996;77:53A-59A.
43. Gaita P, Greco C, Biagioli F, et al: Atrial fibrillation: Propafenone versus quinidine in the long-term prophylaxis. (Abstract) Eur Heart J 1989;10:1-102.
44. Lee S, Chen S, Chiang C, et al: Comparisons of oral propafenone and quinidine as an initial treatment option in patients with symptomatic paroxysmal atrial fibrillation: A double-blind, randomized trial. J Intern Med 1996;236:253-269.
45. Lau C, Leung W, Wong C: A randomized double-blind crossover study comparing the efficacy and tolerability of flecainide and quinidine in the control of patients with symptomatic paroxysmal atrial fibrillation. Am Heart J 1992;124:645-650.
46. Prystowsky EN: Proarrhythmia during drug treatment of supraventricular tachycardia: Paradoxical risk of sinus rhythm for sudden death. Am J Cardiol 1996; 78(Suppl 8A):35-41.
47. van Gelder I, Crijns H, van Gilst W: Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation of atrial flutter. Am J Cardiol 1989;64:1317-1321.
48. Hopson J, Buxton A, Rinkenberger R, et al: Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: Results of a multicenter trial. Am J Cardiol 1996;77:72A-82A.
49. Hellestrand K. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia. Am J Cardiol 1996;77:83A-88A.
50. Rasmussen K, Andersen A, Abrahamsen A et al: Flecainide versus disopyramide in maintaining sinus rhythm following conversion of chronic atrial fibrillation. (Abstract) Eur Heart J 1988;9:52.
51. Chiementi M, Cullen M, Casadei G: Safely of long-term flecainide and propafenone in the management of patients with symptomatic paroxysmal atrial fibrillation: Report from the flecainide and propafenone Italian study investigators. Am J Cardiol 1996;77:60A-65A.
52. Aliot I, Denjoy I: Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/ flutter. Am J Cardiol 1996;77:66A-71A.
53. Anderson J, Gilbert E, Alpert B, et al: Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy: A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Circulation 1989;80:1557-1570.
54. Clementy J, Dulhoste N, Laiter C, et al: Flecainide acetate in the prevention of paroxysmal atrial fibrillation: A nine-month follow-up of more than 500 patients. Am J Cardiol 1992;70:44A-49A.
55. Leclercq J, Chouty F, Denjoy I, et al: Flecainide in quinidine-resistant atrial fibrillation. Am J Cardiol 1992;70:62A-65A.
56. Pietersen A, Helleman H: Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Am J Cardiol 1991;67:713-717.
57. Pritchett E, DaTorre S, Platt M, et al: Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: Dose-response study. J Am Coll Cardiol 1991;17:297-303.
58. Berns E, Rinkenberger R, Jeang M, et al: Efficacy and safety of flecainide acetate for atrial tachycardia or fibrillation. Am J Cardiol 1987;59:1337-1341.
59. Chouty F, Coumel P: Oral flecainide for prophylaxis of paroxysmal atrial fibrillation. Am J Cardiol 1988;62: 35D-37D.
60. Reimold S, Cantillon C, Friedman P, et al: Propafenone versus sotalol for suppression of recurrent symptomatic atrial fibrillation. Am J Cardiol 1993;71:558-563.
61. Antman E, Beamer A, Cantillon C, et al: Therapy of refractory symptomatic atrial fibrillation and atrial flutter: A staged care approach with new antiarrhythmic drugs. J Am Coll Cardiol 1990;15:698-707.
62. Antman E, Beamer A, Cantillon C, et al: Long-term oral propafenone therapy for suppression of refractory symptomatic atrial fribrillation and atrial flutter. J Am Coll Cardiol 1988;12:1005-1011.
63. Stroobandt R, Stiels B, Hoebrechts R: Propafenone for conversion and prophylaxis of atrial fibrillation. Am J Cardiol 1997;79:418-423.
64. Bellandi F, Cantini F, Pedone T, et al: Efficacia del propafenone e dell'amiodarone endovena nella conversione della fibrillazione atriale recente. Follow-up di l anno con trattamento orale. G Ital Cardiol 1998;23:261-271.
65. Crijns H, Gosselink A, Lie K: Propafenone versus disopyramide for maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation: A randomized, double-blind study. Cardiovasc Drugs Ther 1996;10:145-152.
66. Hammil S, Wood D, Gersh B, et al: Propafenone for paroxysmal atrial fibrillation. Am J Cardiol 1988;61: 473-474.
67. Allen F, Brodsky M, Doria R, et al: Oral propafenone therapy for patients with paroxysmal supraventricular tachyarrhythmia. Chest 1988;94:853-854.
68. Kyles A, Murdock C, Yeung-Lai-Wah J, et al: Long-term efficacy of propafenone for prevention of atrial fibrillation. Can J Cardiol 1991;7:407-409.
69. Chun S, Sager P, Stevenson W, et al: Long-term effcacy of amiodarone for the maintenance of normal sinus rhythm in patients with refractory atrial fibrillation or flutter. Am J Cardiol 1995;76:47-50.
70. Gold R, Haffajee C, Charos G: Amiodarone for refractory atrial fibrillation. Am J Cardiol 1986;57:124-127.
71. Graboys T, Podrid P, Lown B: Efficacy of amiodarone for refractory supraventricular tachyarrhythmias. Am Heart J 1983;106:870-875.
72. Haffajee C, Love J, Alpert J, et al: Efficacy and safety of long-term amiodarone in treatment of cardiac arrhythmias: Dosage experience. Am Heart J 1983;106: 935-942.
73. Brodsky M, Allen B, Walker C, et al: Amiodarone for maintenance of sinus rhythm after conversion of atrial fibrillation in the setting of a dilated left atrium. Am J Cardiol 1987;60:572-575.
74. Horowitz L, Spielman S, Greenspan A. et al: Use of amiodarone in the treatment of persistent and paroxysmal atrial fibrillation resistant to quinidine therapy. J Am Coll Cardiol 1985;6:1402-1407.
75. Yee K, Heger J, Prystowsky EN, et al: Predictors of clinical efficacy for amiodarone in supraventricular tachyarrhythmias. (Abstract) Circulation 1981;70:II-438.
76. Gosselink A, Crijns H, van Gelder I, et al: Low-dose amiodarone for maintenance of sinus rhythm after cardioversion of atrial fibrillation or flutter. JAMA 1992; 267:3289-3293.
77. Blevins R, Kerin N, Benaderet D, et al: Amiodarone in the management of refractory atrial fibrillation. Arch Intern Med 1987;147:1401-1404.
78. Ward D, Camm A, Spurell R: Clinical antiarrhythmic effects of amiodarone in patients with resistant paroxysmal tachycardias. Br Heart J 1998;44:91-95.
79. Podrid P, Lown B: Amiodarone therapy in symptomatic sustained refractory atrial and ventricular tachyarrhythmias. Am Heart 1981;101:374-379.
80. Kay NG, Plumb VJ, Arciniegas JG, et al: Torsade de pointes: The long-short initiating sequence and other clinical features: Observations in 32 patients. J Am Coll Cardiol 1983;2:806-817.
81. Makkar RR, Fromm BS, Steinman RT, et al: Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-2597.
82. Kawasaki R, Machado C, Reinochl J, et al: Increased propensity of women to develop torsades de pointes during complete heart block. J Cardiovasc Electrophysiol 1995;6:1032-1038.
83. Lehmann MH, Hardy S, Archibald D, et al: Sex difference in risk of torsade de pointes with d,1-sotalol. Circulation 1996;94:2534-2541.
84. Roden D, Woosley R, Primm R: Incidence and clinical features of the quinidine associated long QT syndrome: Implications for patient care. Am Heart J 1986;111: 1088-1093.
85. McKibbin JK, Pocock WA, Barlow JB: Sotalol, hypokalaemia, syncope, and torsade de pointes. Br Heart J 1984;51:157-162.
86. Hohnloser S, Arentds W, Quart B: Incidence, type, and dose-dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF. (Abstract) PACE 1992;15:551.
87. Roden D: Taking the "idio" out of "idiosyncratic": Predicting torsades de pointes. PACE 1998;21:1029-1034.
88. Middlekauff HR, Stevenson WG, Saxon LA, et al: Amiodarone and torsades de pointes in patients with advanced heart failure. Am J Cardiol 1995;76:499-502.
89. Hohnloser SH, Klingenheben T, Singh BN: Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-535.